These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 31066871)

  • 1. Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review.
    Hofmann Bowman MA; Eagle KA; Milewicz DM
    JAMA Cardiol; 2019 Jul; 4(7):702-707. PubMed ID: 31066871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial.
    Muiño-Mosquera L; De Nobele S; Devos D; Campens L; De Paepe A; De Backer J
    Acta Cardiol; 2017 Dec; 72(6):616-624. PubMed ID: 28657492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
    Gambarin FI; Favalli V; Serio A; Regazzi M; Pasotti M; Klersy C; Dore R; Mannarino S; Viganò M; Odero A; Amato S; Tavazzi L; Arbustini E
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):354-62. PubMed ID: 19430350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan?
    Matt P; Habashi J; Carrel T; Cameron DE; Van Eyk JE; Dietz HC
    J Thorac Cardiovasc Surg; 2008 Feb; 135(2):389-94. PubMed ID: 18242274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome.
    Yang HH; Kim JM; Chum E; van Breemen C; Chung AW
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):305-312.e2. PubMed ID: 20189193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial.
    Radonic T; de Witte P; Baars MJ; Zwinderman AH; Mulder BJ; Groenink M;
    Trials; 2010 Jan; 11():3. PubMed ID: 20067609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutics Targeting Drivers of Thoracic Aortic Aneurysms and Acute Aortic Dissections: Insights from Predisposing Genes and Mouse Models.
    Milewicz DM; Prakash SK; Ramirez F
    Annu Rev Med; 2017 Jan; 68():51-67. PubMed ID: 28099082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis Examining the Usefulness of Angiotensin Receptor blockers for the Prevention of Aortic Root Dilation in Patients With the Marfan Syndrome.
    Al-Abcha A; Saleh Y; Mujer M; Boumegouas M; Herzallah K; Charles L; Elkhatib L; Abdelkarim O; Kehdi M; Abela GS
    Am J Cardiol; 2020 Aug; 128():101-106. PubMed ID: 32650901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.
    Habashi JP; Judge DP; Holm TM; Cohn RD; Loeys BL; Cooper TK; Myers L; Klein EC; Liu G; Calvi C; Podowski M; Neptune ER; Halushka MK; Bedja D; Gabrielson K; Rifkin DB; Carta L; Ramirez F; Huso DL; Dietz HC
    Science; 2006 Apr; 312(5770):117-21. PubMed ID: 16601194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.
    Lacro RV; Dietz HC; Wruck LM; Bradley TJ; Colan SD; Devereux RB; Klein GL; Li JS; Minich LL; Paridon SM; Pearson GD; Printz BF; Pyeritz RE; Radojewski E; Roman MJ; Saul JP; Stylianou MP; Mahony L;
    Am Heart J; 2007 Oct; 154(4):624-31. PubMed ID: 17892982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Clinical Drug Trials Evidence in Marfan Syndrome and Clinical Implications.
    Singh MN; Lacro RV
    Can J Cardiol; 2016 Jan; 32(1):66-77. PubMed ID: 26724512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.
    Cook JR; Clayton NP; Carta L; Galatioto J; Chiu E; Smaldone S; Nelson CA; Cheng SH; Wentworth BM; Ramirez F
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):911-7. PubMed ID: 25614286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Ghent Marfan Trial--a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with β-blockers.
    Möberg K; De Nobele S; Devos D; Goetghebeur E; Segers P; Trachet B; Vervaet C; Renard M; Coucke P; Loeys B; De Paepe A; De Backer J
    Int J Cardiol; 2012 Jun; 157(3):354-8. PubMed ID: 21239069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.
    Chiu HH; Wu MH; Wang JK; Lu CW; Chiu SN; Chen CA; Lin MT; Hu FC
    Mayo Clin Proc; 2013 Mar; 88(3):271-6. PubMed ID: 23321647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicine. Old drug, new hope for Marfan syndrome.
    Travis J
    Science; 2006 Apr; 312(5770):36-7. PubMed ID: 16601163
    [No Abstract]   [Full Text] [Related]  

  • 16. Pravastatin reduces Marfan aortic dilation.
    McLoughlin D; McGuinness J; Byrne J; Terzo E; Huuskonen V; McAllister H; Black A; Kearney S; Kay E; Hill AD; Dietz HC; Redmond JM
    Circulation; 2011 Sep; 124(11 Suppl):S168-73. PubMed ID: 21911808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome.
    Yang HH; Kim JM; Chum E; van Breemen C; Chung AW
    Br J Pharmacol; 2009 Nov; 158(6):1503-12. PubMed ID: 19814725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.
    Brooke BS; Habashi JP; Judge DP; Patel N; Loeys B; Dietz HC
    N Engl J Med; 2008 Jun; 358(26):2787-95. PubMed ID: 18579813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome.
    Detaint D; Aegerter P; Tubach F; Hoffman I; Plauchu H; Dulac Y; Faivre LO; Delrue MA; Collignon P; Odent S; Tchitchinadze M; Bouffard C; Arnoult F; Gautier M; Boileau C; Jondeau G
    Arch Cardiovasc Dis; 2010 May; 103(5):317-25. PubMed ID: 20619242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis.
    Kang YN; Chi SC; Wu MH; Chiu HH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):182-190. PubMed ID: 31003918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.